About Karuna Therapeutics
Karuna Therapeutics is a company based in Boston (United States) founded in 2009 was acquired by Bristol-Myers Squibb in December 2023. Karuna Therapeutics has raised $132.1 million across 6 funding rounds from investors including Fidelity Investments, ARE and PureTech Health. The company has 339 employees as of February 29, 2024. Karuna Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Boston, United States
- Employees 339 as on 29 Feb, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Karuna Therapeutics, Inc.
-
Annual Revenue
$654 K (USD)-94as on Dec 31, 2023
-
Net Profit
-$433.68 M (USD)-57as on Dec 31, 2023
-
EBITDA
-$494.78 M (USD)-71as on Dec 31, 2023
-
Total Equity Funding
$132.1 M (USD)
in 6 rounds
-
Latest Funding Round
$12 M (USD), Series B
Apr 01, 2019
-
Investors
Fidelity Investments
& 10 more
-
Employee Count
339
as on Feb 29, 2024
-
Acquired by
Bristol-Myers Squibb
(Dec 22, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Karuna Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
394 people
Software Development Team
340 people
Senior Team
99 people
Product Management Team
97 people
Operations Team
83 people
Data Analysis and Operations Team
60 people
Sales and Marketing
58 people
Human Resources and Administration
45 people
Unlock access to complete
Funding Insights of Karuna Therapeutics
Karuna Therapeutics has successfully raised a total of $132.1M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $12 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Karuna Therapeutics
Karuna Therapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, ARE and PureTech Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Growth stage tech & life sciences focused VC Firm investing in Asia and the US
|
Locked | Locked | Locked |
Investor details for Karuna Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Karuna Therapeutics
Investment portfolio details for Karuna Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Karuna Therapeutics
Detailed financials for Karuna Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Karuna Therapeutics Comparisons
Peer comparison for Karuna Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Karuna Therapeutics
Karuna Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of Karuna Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Karuna Therapeutics
Complete news archive for Karuna Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Karuna Therapeutics
Karuna Therapeutics was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Karuna Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Steven M Paul is the current CEO of Karuna Therapeutics.
Karuna Therapeutics is a funded company, having raised a total of $132.1M across 6 funding rounds to date.
As of Feb 29, 2024, the latest employee count at Karuna Therapeutics is 339.
Annual revenue of Karuna Therapeutics is $654K as on Dec 31, 2023.
Karuna Therapeutics was founded in 2009 and is headquartered in Boston, United States. Focus is placed on developing pharmaceutical therapies within the biotechnology sector to address psychosis and cognitive impairment. Operations center on advancing muscarinic receptor agonists, with KarXT serving as a key oral candidate targeted at schizophrenia and psychosis associated with Alzheimers disease. Clinical development and regulatory efforts are conducted primarily in the U.S.
Karuna Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Karuna Therapeutics has 11 investors. Key investors include Fidelity Investments, ARE, PureTech Health, Arch Venture Partners, and Bristol-Myers Squibb.